苏州第三制药厂有限责任公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
48
NMPA:48
Drug Approvals
Fluvoxamine Maleate Tablets
- Product Name
- 马来酸氟伏沙明片
- Approval Number
- 国药准字H20254177
- Approval Date
- May 13, 2025
NMPA
Fluvoxamine Maleate Tablets
- Product Name
- 马来酸氟伏沙明片
- Approval Number
- 国药准字H20254176
- Approval Date
- May 13, 2025
NMPA
Cefprozil for Suspension
- Product Name
- 头孢丙烯干混悬剂
- Approval Number
- 国药准字H20244104
- Approval Date
- Jun 25, 2024
NMPA
Cefprozil for Suspension
- Product Name
- 头孢丙烯干混悬剂
- Approval Number
- 国药准字H20244105
- Approval Date
- Jun 25, 2024
NMPA
Cefaclor for Suspension
- Product Name
- 头孢克洛干混悬剂
- Approval Number
- 国药准字H20243732
- Approval Date
- May 21, 2024
NMPA
Dapoxetine Hydrochloride Tablets
- Product Name
- 盐酸达泊西汀片
- Approval Number
- 国药准字H20234305
- Approval Date
- Oct 18, 2023
NMPA
Dapoxetine Hydrochloride Tablets
- Product Name
- 盐酸达泊西汀片
- Approval Number
- 国药准字H20234304
- Approval Date
- Oct 18, 2023
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
Clinical Trials
No trials found
News
No news found